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  Sitagliptin is an oral hypoglycemic agent with characteris-
tics that may make it particularly useful for treating type 2 dia-
betes mellitus (T2DM) [1]. The drug is a selective inhibitor of 
the enzyme dipeptidyl peptidase-4 (DPP-4) [2], which inacti-
vates the incretins glucagon-like peptide-1 and glucose-depen-
dent insulinotropic peptide. By inhibiting the activity of DPP-4, 
sitagliptin stabilizes the active forms of these incretins, thereby 
supporting glucose homeostasis through mechanisms that are 
not in themselves likely to trigger hypoglycemia [3]. Previous 
randomized placebo-controlled clinical trials have shown that 
sitagliptin is an effective glucose lowering agent in patients with 
T2DM when used as monotherapy and when given in combi-
nation with other drugs such as metformin, sulfonylurea and 
thiazolidinediones [4-7]. In a meta-analysis of 18 randomized 
controlled trials, patients were more likely to reach the HbA1c 
goal of <7% when treated with sitagliptin compared with pla-
cebo (POR, 3.15; 95% confidence interval [CI], 2.47 to 3.72); 
sitagliptin was also associated with greater decline in HbA1c 
from baseline compared with placebo (WMD, -0.78%; 95% 
CI, -0.93 to -0.63) [8]. That study reported that sitagliptin 
treatment lead to improvements in glycemic control in pa-
tients with T2DM, including reductions in HbA1c 0.7 to 1.2%, 
and 17 to 63% of patients achieved HbA1c <7% at the end of 
the treatment. 
  In our study, treatment with 100 mg sitagliptin with metfor-
min or sulfonylurea for 24 weeks led to additional reductions 
of mean HbA1c to 1.23±1.15%. The likelihood of patients to 
reach the HbA1c goal of <7% with sitagliptin treatment was 
47% at the end of 24 weeks. This glycemic lowering effect is 
greater than that observed in previous studies [9,10]. In addi-
tion, the HbA1c lowering effect of sitagliptin was more pro-
nounced in non-obese patients and in patients with decreased 
insulin secretion compared with the non-responder group. 
This potent effects of sitagliptin are expected in Korean dia-
betic patients who have quantitative pancreatic deficiencies. 
Asian T2DM patients have relatively lower level of  pancreatic 
secretory dysfunction than patients of European descent. 
Most studies of sitagliptin have demonstrated significant im-
provements in β-cell function [11,12]. Therefore, sitagliptin 
appears to be effective for the treatment of T2DM, and may 
become a first-line treatment in the future.
  As Dr. Oh noted, our study has some limitations. It is retro-
spective, and did not control for other factors such as exercise 
and diet. Despite these limitations, the results of our study in-
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dicate that sitagliptin treatment greatly reduces glucose level 
in younger, non-obese Korean T2DM patients. Further pro-
spective studies with larger sample sizes are needed to deter-
mine the specific effects of sitagliptin.
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